查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596215

呼吸系統疾病檢測市場：按產品和應用分類 - 2025-2030 年全球預測

Respiratory Disease Testing Market by Product (Blood Gas Test, Imaging Tests, Respiratory Measurement), End-Use (Clinical Laboratories, Hospitals, Physician Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，呼吸系統疾病檢測市場價值為40.8億美元，預計到2024年將達到42.6億美元，複合年成長率為4.43%，到2030年預計將達到55.3億美元。

呼吸系統疾病檢測包括用於識別影響呼吸系統的感染疾病和慢性疾病的多種診斷方法。它包括肺活量測定、血液氣體分析、診斷影像和分子診斷等各種測試，這些測試對於檢測氣喘、慢性阻塞性肺病、結核病和 COVID-19 等疾病至關重要。這些測試對於有效的疾病管理、早期診斷和個人化治療至關重要，對醫療保健提供者和患者都有影響。由於污染、生活方式的改變和人口老化，全球呼吸系統疾病的盛行率不斷增加，對準確、高效的檢測解決方案的需求不斷成長。關鍵的成長要素包括診斷技術的進步、醫療保健支出的增加以及對早期診斷益處的認知的提高。此外，COVID-19 大流行凸顯了對快速、可靠的呼吸系統檢測的需求，從而促進了市場的顯著擴張和創新。開發用於即時分析的就地檢驗設備和整合人工智慧工具存在機會，可提供個人化和預測性見解。然而，市場擴張面臨著監管障礙、先進診斷工具的高成本以及需要熟練的專業人員操作先進測試設備的挑戰。由於醫療基礎設施有限，新興國家也面臨限制。可以透過專注於攜帶式和侵入性較小的測試方法、整合數位健康解決方案以及對生物標記物進行研究以實現更準確的診斷來促進創新。在技​​術不斷進步和對高效診斷解決方案的高需求的推動下，市場充滿活力。相關人員必須投資於研究和開發，以利用這些進步，建立策略夥伴關係關係以提高市場滲透率，並確保遵守監管標準，以有效地利用新的機會。專注於降低成本和提高可及性可以顯著加速市場進入並解決現有挑戰。

主要市場統計
基準年[2023] 40.8億美元
預測年份 [2024] 42.6億美元
預測年份 [2030] 55.3億美元
複合年成長率（%） 4.43%

市場動態：快速發展的呼吸道疾病檢測市場的關鍵市場洞察

供需的動態交互作用正在改變呼吸系統疾病檢測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 呼吸道疾病增加
    • 採取不健康的生活方式和習慣，例如吸煙
    • 空氣污染程度持續上升
    • 主要採用影像技術進行診斷
  • 市場限制因素
    • 替代系統和設備的可用性
  • 市場機會
    • 人們越來越偏好遠端或居家照護測試設備
    • 研究開發測試方法和技術進步以獲得有效、高效、快速的結果
  • 市場挑戰
    • 缺乏保險報銷政策

波特五力：駕馭呼吸道疾病檢測市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解呼吸系統疾病檢測市場的外部影響

外部宏觀環境因素對呼吸系統疾病檢測市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解呼吸系統疾病檢測市場的競爭狀況

對呼吸系統疾病檢測市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣呼吸系統疾病檢測市場供應商的績效評估

FPNV定位矩陣是評估呼吸道疾病檢測市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃呼吸系統疾病檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對呼吸系統疾病檢測市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 呼吸道疾病發生率上升
      • 採取不健康的生活方式和習慣，例如吸煙
      • 空氣污染水平持續上升
      • 大規模部署影像診斷技術
    • 抑制因素
      • 替代系統和設備的可用性
    • 機會
      • 遠端或居家照護測試設備越來越受歡迎
      • 研究和開發測試方法和技術進步，以獲得有效、高效和快速的結果。
    • 任務
      • 缺乏支持性報銷政策
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章呼吸系統疾病檢測市場：依產品

  • 血氣測試
  • 影像檢查
  • 呼吸測量

第7章呼吸系統疾病檢測市場：依最終用途分類

  • 臨床實驗室
  • 醫院
  • 醫生診所

第8章 北美和南美呼吸疾病檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區呼吸道疾病檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲呼吸道疾病檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerieux
  • Cosmed
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Hitachi Medical Corporation
  • Koninklijke Philips NV
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Thermo Fisher Scientific
Product Code: MRR-035AB9C0DAAD

The Respiratory Disease Testing Market was valued at USD 4.08 billion in 2023, expected to reach USD 4.26 billion in 2024, and is projected to grow at a CAGR of 4.43%, to USD 5.53 billion by 2030.

Respiratory disease testing encompasses a broad range of diagnostic methods used to identify infections and chronic conditions affecting the respiratory system. The scope includes various tests like spirometry, blood gas analysis, imaging, and molecular diagnostics, imperative in detecting ailments such as asthma, COPD, tuberculosis, and COVID-19. These tests are essential for effective disease management, early diagnosis, and treatment personalization, impacting both healthcare providers and patients. With an increasing prevalence of respiratory diseases globally due to pollution, lifestyle changes, and aging populations, the demand for accurate and efficient testing solutions is escalating. Key growth influencers include technological advancements in diagnostics, rising healthcare expenditure, and increased awareness of early diagnosis benefits. Moreover, the COVID-19 pandemic has underscored the necessity for rapid and reliable respiratory testing, prompting substantial market expansion and innovation. Opportunities lie in the development of point-of-care testing devices and integrated AI tools for real-time analytics, providing personalized and predictive insights. However, market expansion is challenged by regulatory hurdles, the high cost of advanced diagnostic tools, and the need for skilled professionals to operate sophisticated testing equipment. Emerging economies also face constraints due to limited healthcare infrastructure. Innovation can thrive by focusing on portable and less invasive testing methods, integrating digital health solutions, and conducting research on biomarkers for more precise diagnostics. The market is dynamic, driven by the constant evolution of technology and the high demand for efficient diagnostic solutions. Stakeholders need to invest in R&D to leverage these advances, adopt strategic partnerships to enhance market penetration, and ensure compliance with regulatory standards to capitalize on emerging opportunities effectively. The emphasis on reducing costs and improving accessibility can significantly enhance market reach and address existing challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 4.08 billion
Estimated Year [2024] USD 4.26 billion
Forecast Year [2030] USD 5.53 billion
CAGR (%) 4.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Disease Testing Market

The Respiratory Disease Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of respiratory diseases
    • Adoption of unhealthy lifestyle and habits such as tobacco smoking
    • Constantly rising air pollution levels
    • Major adoption of imaging technology for diagnostics
  • Market Restraints
    • Availability of alternatives systems and devices
  • Market Opportunities
    • Rising preferences for remote or home care testing devices
    • R&D and technology advancements in testing methods for effective, efficient, and faster results
  • Market Challenges
    • Lack of supportive reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Disease Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Disease Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Disease Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Disease Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Disease Testing Market

A detailed market share analysis in the Respiratory Disease Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Disease Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Disease Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Disease Testing Market

A strategic analysis of the Respiratory Disease Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux, Cosmed, F. Hoffmann-La Roche Ltd., Fujifilm Holdings, GE Healthcare, Hitachi Medical Corporation, Koninklijke Philips N.V, Medtronic PLC, MGC Diagnostics Corporation by Caire Inc., ResMed, SDI Diagnostics, Inc., Seegene Inc., and Thermo Fisher Scientific.

Market Segmentation & Coverage

This research report categorizes the Respiratory Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Blood Gas Test, Imaging Tests, and Respiratory Measurement.
  • Based on End-Use, market is studied across Clinical Laboratories, Hospitals, and Physician Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of respiratory diseases
      • 5.1.1.2. Adoption of unhealthy lifestyle and habits such as tobacco smoking
      • 5.1.1.3. Constantly rising air pollution levels
      • 5.1.1.4. Major adoption of imaging technology for diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternatives systems and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising preferences for remote or home care testing devices
      • 5.1.3.2. R&D and technology advancements in testing methods for effective, efficient, and faster results
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of supportive reimbursement policies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Respiratory Disease Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Blood Gas Test
  • 6.3. Imaging Tests
  • 6.4. Respiratory Measurement

7. Respiratory Disease Testing Market, by End-Use

  • 7.1. Introduction
  • 7.2. Clinical Laboratories
  • 7.3. Hospitals
  • 7.4. Physician Clinics

8. Americas Respiratory Disease Testing Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Respiratory Disease Testing Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Respiratory Disease Testing Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Becton, Dickinson and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Biomerieux
  • 5. Cosmed
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Fujifilm Holdings
  • 8. GE Healthcare
  • 9. Hitachi Medical Corporation
  • 10. Koninklijke Philips N.V
  • 11. Medtronic PLC
  • 12. MGC Diagnostics Corporation by Caire Inc.
  • 13. ResMed
  • 14. SDI Diagnostics, Inc.
  • 15. Seegene Inc.
  • 16. Thermo Fisher Scientific

LIST OF FIGURES

  • FIGURE 1. RESPIRATORY DISEASE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. RESPIRATORY DISEASE TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESPIRATORY DISEASE TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD GAS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY MEASUREMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PHYSICIAN CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023